Proton Pump Inhibitor and Antibiotic Use May Reduce the Benefit of Immunotherapy in NSCLC
Baseline use of proton pump inhibitors (PPIs) and, to a lesser extent, antibiotics was associated with poorer outcomes in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with durvalumab after chemoradiotherapy, suggesting these medications may reduce the benefit of immunotherapy. This post-hoc analysis of the phase 3 […]